Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse ModelOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether transferring gut bacteria from human donors with different Alzheimer's disease (AD) risk profiles could alter behavior and brain pathology in a mouse model of AD. Researchers used fecal microbiota transplantation (FMT) to introduce donor microbiota into female 3xTgAD mice over a two-month period with weekly dosing. They then measured cognitive and behavioral outcomes alongside brain amyloid, tau pathology, and neuroinflammation. The design compared microbiota from an AD patient, a cognitively healthy carrier of the protective APOEe2 allele, a young healthy donor, and untreated mice.
Who was studied?
The human donors were an 80-year-old patient with AD, a 73-year-old cognitively healthy individual carrying the protective APOEe2 allele, and a 22-year-old healthy young donor. The animal subjects were female 3xTgAD mice, a transgenic model that develops AD-like amyloid and tau pathology, divided into four FMT groups (AD-FMT, APOEe2-FMT, Young-FMT, and untreated Mice-FMT). No human cognitive or clinical outcomes were assessed; the study population for outcome measures was entirely the mouse cohort.
What were the most important findings?
Mice receiving APOEe2-FMT showed improved short-term recognition memory on the novel object recognition test compared to mice receiving AD-FMT, though no significant differences appeared on the Y-maze, open-field, or elevated plus maze tests. This cognitive improvement was accompanied by increased neuroinflammation in the hippocampus, detected via translocator protein autoradiography, with no corresponding change in brain amyloid or tau pathology. Specific bacterial genera, including Parabacteroides and Prevotellaceae_UGC001, were enriched in the APOEe2-FMT group and were associated with the neuroinflammatory changes.
What are the greatest implications of this study?
The findings suggest that gut microbiota from a donor with AD-protective genetic factors can influence memory function in an AD mouse model, but the relationship between microbiota, cognition, and neuroinflammation is not straightforward. Improved memory occurred alongside increased neuroinflammation rather than reduced pathology, indicating that neuroinflammatory changes are not simply harmful or protective in this context. This highlights the need for caution when interpreting FMT as a uniformly beneficial intervention and points to specific bacterial genera as candidates for further mechanistic investigation.